Quantcast

Latest Oxford BioMedica Stories

2011-06-22 01:00:00

OXFORD, England, June 22, 2011 /PRNewswire/ -- - RetinoStat(R) Progress in Phase I Study in Wet Age-Related Macular Degeneration Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene therapy company, today announces that the first dose level of RetinoStat(R) is safe and well-tolerated at one month following treatment. RetinoStat(R) is a novel gene-based treatment for neovascular "wet" age-related macular degeneration (AMD), designed and...

2011-06-06 11:53:00

OXFORD, United Kingdom, June 6, 2011 /PRNewswire/ -- Oxford BioMedicaplc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene therapy company, today announces that it has signed a research collaboration agreement with ImaginAb, Inc. ("ImaginAb"), a biotechnology company specialising in the development of engineered antibody fragments for diagnostic imaging and novel therapeutic applications, to engineer an in vivo diagnostic imaging agent using an antibody targeting the...

2011-05-23 01:00:00

OXFORD, England, May 23, 2011 /PRNewswire-FirstCall/ -- - Six-Month Data From Third Cohort Presented at ASGCT 14th Annual Meeting - - Highest Efficacy Results to Date With 43% Average Motor Function Improvement - Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene therapy company, announces that new data from the on-going Phase I/II trial of ProSavin(R) for the treatment of Parkinson's disease (PD) were presented at the American Society of...

2011-03-15 02:00:00

OXFORD, England, March 15, 2011 /PRNewswire-FirstCall/ -- - Immune Response Surrogate Algorithm Shownto be a Significant Predictor of Clinical Benefit Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene therapy company, today announces that further analyses of the TroVax(R) Renal Immunotherapy Survival Trial ("TRIST"), a randomised, double-blind, placebo-controlled Phase III study, have been accepted for publication in Cancer Immunology,...

2010-01-27 07:00:00

CAMBRIDGE, Mass. and OXFORD, England, Jan. 27 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute and Oxford BioMedica (LSE: OXB) announced today the extension of their collaboration following successful completion of the first phase. The extended collaboration, which is funded by the Muscular Dystrophy Association, aims to advance the development of Oxford BioMedica's preclinical gene therapy candidate, MoNuDin®, and to evaluate other gene-based strategies...


Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related